Clinical trial
Bendamustine and Rituximab in Treating Patients With Previously Untreated or…
NCT00274989 · German CLL Study Group, Other · Completed
Key facts
| NCT number | NCT00274989 |
|---|---|
| Title | Bendamustine and Rituximab in Treating Patients With Previously Untreated or Relapsed Chronic Lymphocytic Leukemia |
| Official title | Multicentre Phase II Trial of Bendamustine in Combination With Rituximab for Patients With Previously Untreated or Relapsed Chronic Lymphocytic Leukemia. CLL2M Protocol of the German CLL-Study Group (GCLLSG) |
| Lead sponsor | German CLL Study Group, Other |
| Collaborators | University of Cologne |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Lymphocytic Leukemia |
| Intervention type | Biological, Drug |
| Interventions | Bendamustine, Rituximab |
| Enrollment | 195 |
| Start date | Nov 1, 2005 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2011 |
| First posted | Jan 11, 2006 |
| Last update posted | May 23, 2019 |
| Countries | Germany |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: